Hollingsworth Brynn A, Cassatt David R, DiCarlo Andrea L, Rios Carmen I, Satyamitra Merriline M, Winters Thomas A, Taliaferro Lanyn P
Radiation and Nuclear Countermeasures Program (RNCP), Division of Allergy, Immunology and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Rockville, MD, United States.
Front Pharmacol. 2021 May 18;12:643283. doi: 10.3389/fphar.2021.643283. eCollection 2021.
Study of the human microbiota has been a centuries-long endeavor, but since the inception of the National Institutes of Health (NIH) Human Microbiome Project in 2007, research has greatly expanded, including the space involving radiation injury. As acute radiation syndrome (ARS) is multisystemic, the microbiome niches across all areas of the body may be affected. This review highlights advances in radiation research examining the effect of irradiation on the microbiome and its potential use as a target for medical countermeasures or biodosimetry approaches, or as a medical countermeasure itself. The authors also address animal model considerations for designing studies, and the potential to use the microbiome as a biomarker to assess radiation exposure and predict outcome. Recent research has shown that the microbiome holds enormous potential for mitigation of radiation injury, in the context of both radiotherapy and radiological/nuclear public health emergencies. Gaps still exist, but the field is moving forward with much promise.
对人类微生物群的研究已经历经了几个世纪,但自2007年美国国立卫生研究院(NIH)开展人类微生物组计划以来,相关研究有了极大扩展,其中包括涉及辐射损伤的领域。由于急性放射综合征(ARS)是多系统的,身体所有部位的微生物群落生态位都可能受到影响。本综述重点介绍了辐射研究方面的进展,这些研究探讨了辐射对微生物群的影响及其作为医学对策或生物剂量测定方法的靶点,或其本身作为一种医学对策的潜在用途。作者还讨论了设计研究时动物模型的考量因素,以及将微生物群用作生物标志物以评估辐射暴露和预测结果的可能性。最近的研究表明,在放射治疗以及放射/核公共卫生紧急情况的背景下,微生物群在减轻辐射损伤方面具有巨大潜力。差距仍然存在,但该领域正满怀希望地向前发展。